Researchers at Mount Sinai Hospital have demonstrated that a machine learning-based model enables medical institutions to predict mortality risk for individual cardiac surgery patients.

Tissium SA reported the close of a series D funding round, raising $54 million from investors both new – such as Mérieux Développement SAS – and long-term, including Cathay Capital Co. Ltd., Crédit Mutuel Innovation SAS and original investors, Sofinnova Partners SAS.

Researchers from the French institute of health and medical research (INSERM) and the University of Bordeaux, France, have developed an artificial intelligence (AI) tool to leverage hospital data for trauma patients. They have published results for a new algorithm capable of classifying trauma-related emergency room visits in the Journal of Medical Internet Research – Artificial Intelligence. “Thanks to this new AI tool, we have generated highly accurate data that allows us to accurately classify the mechanisms of trauma, which represent one third of emergency room visits in France,” said Gabrielle Chenais, research specialist and data scientist at the Bordeaux Population Health (BPH) Research Centre. BPH is a research body run by INSERM and the University of Bordeaux.

Moon Surgical SAS secured a new $55.4 million round of financing to strengthen the development and commercialization of its Maestro robotic system for laparoscopic surgery.

The French National Authority for Health, known in France as the Haute Autorité de la Santé (HAS), recently published a favorable opinion regarding reimbursement for the first diagnostic test to benefit under an innovation initiative. The test is the Metaglut1 test from Metafora Biosystems SAS, a non-invasive diagnostic test that identifies glucose transporter type 1 deficiency syndrome (Glut1DS).

Regenlife SAS raised $3.3 million in series A funding in order to finalize the development of its photomodulation technology to treat neurodegenerative diseases.

Olympus Europa SE & Co. KG is launching three Endoclot products, two hemostatic agents and a submucosal injection agent, in the Europe, Middle East and Africa (EMEA) region. This new portfolio was developed by Santa Clara, Calif.-based Endoclot Plus Inc., which expanded its distribution with Olympus from the U.S. to EMEA in December 2022. “The addition of their solutions to our portfolio allows Olympus to contribute to safe treatment in gastrointestinal procedures. We aim to improve patient outcomes and hereby elevate the standard of care,” said Stefanie Kaufung, EMEA business unit manager gastrointestinal endotherapy at Olympus.

Quantum Surgical SAS has obtained an extension to the FDA authorization covering its Epione robot, which can now treat abdominal cancers. “This decision now allows physicians to treat all abdominal tumors at an early stage and will ramp implementation of our Epione robotics solution in the U.S.,” said Bertin Nahum, CEO and co-founder of Quantum Surgical. Marketed in Europe and the U.S., the Epione robot has already been used to treat more than 150 patients with liver or kidney cancer.

Aidoc Medical Ltd. has just presented a study using its AI tool in the Netherlands Cancers Institute for detection and worklist prioritization to diagnose incidental pulmonary embolism at routine contrast-enhanced chest CT. The results published in Radiology: Cardiothoracic Imaging show a reduction by 15% of the missed rate of incidental pulmonary embolism and by more than 98% of the notification time for positive incidental pulmonary embolism. “Our AI system gives a response related to the interpretation, quantification and workflow management,” Elad Walach, co-founder and CEO of Aidoc Medical, told BioWorld. Due to the growing volume of radiology examinations, particularly in thoracic imaging, and the lack of supply radiologists, the delay between the CT examinations and their interpretation has increased significantly in many practices. This is particularly true for pulmonary embolism (PE).

Magenta Medical Ltd. has raised $55 million to fast-track the development of the world’s smallest left ventricular assist device (LVAD). The financing round was led by Orbimed Private Investment LLC. With the participation of existing investors, New Enterprise Associates, Pitango VC Ltd. and Alive MS Ltd. “We will use this funding, in particular, to advance the clinical programs in the U.S. towards our first FDA approval,” David Israeli, CEO of Magenta Medical, told BioWorld.